Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Acq. announced
Consulting agrmnt
|
|
Enliven Therapeutics, Inc. (IMRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Sold 12,000 shares
@ $13.6248, valued at
$163.5k
Exercised 12,000 options to buy
@ $1.12, valued at
$13.4k
|
|
| 09/28/2023 |
4
| 5AM Partners VI, LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Sold 164,789 shares
@ $15, valued at
$2.5M
Sold 32,711 shares
@ $15, valued at
$490.7k
|
|
| 09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
| 05/19/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Exercised 2,125 options to buy
@ $4.28, valued at
$9.1k
|
|
| 03/06/2023 |
3
| 5AM Partners VI, LLC (10% Owner) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
4
| Schwab Andrew J. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 4,838,092 shares
@ $0
Granted 960,383 shares
@ $0 |
|
| 02/27/2023 |
4
| Heyman Richard A. (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 149,820 shares
@ $0
Granted 37,407 shares
@ $0
Granted 31,172 shares
@ $0
Granted 20,657 options to buy
@ $2.48, valued at
$51.2k
|
|
| 02/27/2023 |
3
| Heyman Richard A. (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
4
| Gupta Rishi (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 7,611,458 shares
@ $0
Granted 288,114 shares
@ $0 |
|
| 02/27/2023 |
4
| Bauer Jake (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 87,372 shares
@ $0
Granted 17,706 options
@ $2.48, valued at
$43.9k
|
|
| 02/27/2023 |
3
| Schwab Andrew J. (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Phillips Andrew John (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Gupta Rishi (10% Owner) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Derynck Mika K (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Bauer Jake (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
4
| Derynck Mika K (Director) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 87,373 options to buy
@ $2.48, valued at
$216.7k
|
|
| 02/27/2023 |
4
| Patel Anish (COO) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 36,722 shares
@ $0
Granted 394,027 shares
@ $0
Granted 10,767 options to buy
@ $1.12, valued at
$12.1k
Granted 2,827 options to buy
@ $2.48, valued at
$7k
Granted 75,620 options to buy
@ $2.48, valued at
$187.5k
|
|
| 02/27/2023 |
4
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 1,117,035 shares
@ $0
Granted 344,550 options to buy
@ $1.12, valued at
$385.9k
Granted 88,531 options to buy
@ $2.48, valued at
$219.6k
|
|
| 02/27/2023 |
4
| Hohl Benjamin (CFO) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 262,120 options to buy
@ $2.48, valued at
$650.1k
|
|
| 02/27/2023 |
4
| Kintz Samuel (President and CEO) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 1,087,525 shares
@ $0
Granted 88,531 shares
@ $0
Granted 88,531 shares
@ $0
Granted 344,550 options to buy
@ $1.12, valued at
$385.9k
Granted 404,363 options to buy
@ $2.48, valued at
$1M
|
|
| 02/27/2023 |
4
| Collins Helen Louise (Chief Medical Officer) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 287,084 options to buy
@ $2.48, valued at
$712k
|
|
| 02/27/2023 |
3
| Kintz Samuel (President and CEO) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Patel Anish (COO) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Lyssikatos Joseph P (Chief Scientific Officer) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Hohl Benjamin (CFO) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Collins Helen Louise (Director) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
3
| Kintz Samuel (President and CEO) has filed a Form 3 on Enliven Therapeutics, Inc. |
| 02/27/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 7,611,458 shares
@ $0
Granted 288,114 shares
@ $0 |
|
| 02/27/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Bought 622 shares
@ $22.072, valued at
$13.7k
Acquired 729,891 shares
@ $0 |
|
| 02/27/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Former 10% owner) has filed a Form 4 on Enliven Therapeutics, Inc.|
Txns:
| Granted 1,152,460 shares
@ $0 |
|
| 02/23/2023 |
4
| COMMODORE CAPITAL LP (10% Owner) has filed a Form 4 on IMARA Inc.|
Txns:
| Bought 8,194 shares
@ $5.249, valued at
$43k
Bought 23,565 shares
@ $5.113, valued at
$120.5k
|
|
| 02/22/2023 |
4
| GRAY MICHAEL (CFO & COO) has filed a Form 4 on IMARA Inc.|
Txns:
| Sold 9,856 shares
@ $4.67, valued at
$46k
|
|
| 02/22/2023 |
4
| Ballal Rahul D. (CEO) has filed a Form 4 on IMARA Inc.|
Txns:
| Sold 32,861 shares
@ $4.66, valued at
$153.1k
|
|
|
|
|